Browsing Tag
MedinCell
4 posts
Why Teva’s once-monthly olanzapine shot could finally change how schizophrenia is treated in the U.S.
Find out how Teva’s FDA-accepted once-monthly olanzapine injection could reshape schizophrenia care and what investors and clinicians will watch next.
Teva’s new bipolar breakthrough: FDA clears UZEDY as the first monthly long-acting risperidone
Teva’s UZEDY long-acting injectable gains FDA approval for bipolar I maintenance, reshaping psychiatric treatment and investor sentiment.
Medincell’s Phase 3 trial for long-acting injectable olanzapine in schizophrenia reaches completion
Medincell has announced the successful completion of the pivotal Phase 3 SOLARIS clinical trial for its long-acting injectable…
Teva Pharmaceuticals, MedinCell get UZEDY FDA approval for schizophrenia
Teva Pharmaceuticals and MedinCell have bagged approval for UZEDY (risperidone) extended-release injectable suspension from the US Food and…